Home  /  Resource Library  /  Treatment of Relapsed/Refractory CLL Patients With PI3K Inhibitor and Anti-CD20 Antibody Rapidly Decreases Tumor Burden but Could Induce Resistance

Treatment of Relapsed/Refractory CLL Patients With PI3K Inhibitor and Anti-CD20 Antibody Rapidly Decreases Tumor Burden but Could Induce Resistance

Results of a study investigating venetoclax combined with ublituximab and umbralisib for treatment of relapsed CLL.